Centrum Farmakoekonomiki is the independent research organisation specializing in outcomes studies, costing studies, economic evaluation, HTA reports and modeling since 1997. It is located in Warsaw and cooperates with a number of Polish authorities, scientifical societies, researchers from the field of pharmacoeconomics and pharmacology, and clinicians.

 

Our misssion is to provide a superior level of quality and expertise in the design and execution of health care research. Our advantage is the adherence to rigorous methodological practices combined with the application of utmost integrity in everything we do.

 

The leader of the company is Ewa Orlewska MD, PhD with large scientifical experience in basic sciences and clinics (the author of textbooks for students and graduets of Medical Universities, projects of Polish guidelines for conducting pharmacoeconomic analyses, financial analyses and cost calculation in the economic evaluations of healthcare programs).
 

The company is able to deliver full service on collecting, management of the
pharmacoeconomical data, monitoring the PE studies, including protocol-writing, site-management, statistical analyses, lectures, organisation of investigators meetings and medical writing both in Polish and in English. The well established contacts in Polish medical and pharmaceutical society guarantee the high level of confidence and delivery of high quality of the data collected during the PE trials.

 

We publish extensively in  top ranked journals including PharmacoEconomics, Value in Health, European Journal of Health Economics, Expert Review of Pharmacoeconomics and Outcomes Research, European Journal of Neurology, Transplantation Proceedings and many others.

 

Our services

  • Outcomes studies
  • Costing studies
  • Economic evaluation
  • Modeling
  • HTA reports
  • Data Management
  • Training

 

Cooperation

 

  1. WHO Regional Office in Europe: Generic Pricing Survey (2002)
  2. M-TAG  : Oncology cost collection Poland (2002)
  3. MEDTAP International:  Cardiovascular cost collection Poland  (2003),  Cost of blood donation in Poland (2004).
  4. Institute for Medical Technology Assessment (iMTA) Erasmus MC, Erasmus University, Rotterdam: Utilization of resources and costs related to cardiovascular diseases in Poland (2004)
  5. Post-marketing Drug Evaluation Centre Chinese Cochrane Collaboration, Hongkong: Economic evaluation of antiviral therapy for HBV infection in China (2004).

 

Most important publications:

 

I.   Costing studies:

  1. Czechowicz-Janicka K, Orlewska E, Tobota Z, Anielska E, Dyczkowska A. Analysis of glaucoma therapy cost in Poland – population of Mazovian District. Klinika Oczna 2000, 102(6): 4177-22.
  2. Orlewska E, Mierzejewski P, et al. Cost of multiple sclerosis in Poland . Eur J Neurol 2004 (in press)

 

 

II. Cost-effectiveness analyses:

      

  1. Orlewska E. Arthrotec 75 versus diklofenak SR 75: analiza koszty-efektywność (The cost-effectiveness of Arthrotec 75 versus diclofenac SR 75 in the treatment of rheumatoid arthritis and osteoarthritis in Poland. Farmakoekonomika 2000, 1: 2-18.
  2. Orlewska E. The cost-effectiveness of alternative therapeutic strategies for management of chronic hepatitis B in Poland. Value in Health 2002, 5(5): 404-420
  3. Orlewska E., Budaj A., Tereszkowski-Kamiński D. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in acute coronary syndrome patients in Poland. Pharmacoeconomics, 2003; 21(10): 737-48.
  4. Orlewska E, Zaborowski P. Koszty I efekty terapii skojarzonej pegylowanym interferonem alfa-2a z rybawiryną w porównaniu do standardowej terapii skojarzonej interferonem alfa-2b alfa rynawiryną w przewlekłym wirusowym zapaleniu wątroby typu C u dorosłych w Polsce (The cost and effects of combination of peginterferon alfa-2a and ribavirin versus combination of conventional interferon (alfa-2b) nd ribavirin In chronic hepatitis C In adults in Poland. Farmakoekonomika 2003, 4: 3-15.
  5. Orlewska E. Analiza efektywności kosztów przedłużonej profilaktyki przeciwzakrzepowej enpoksaparyną u chorych poddanych zabiegowi planowej alloplastyki stawu biodrowego w Polsce (The cost-effectiveness analysis of extended venous thromboembolism prophylaxis with enoxaparin versus short-term prophylaxis after elctive hip replacement In Poland). Farmakoekonomika 2004, 2: 3-12.

 

 

III. Methodology:

 

  1. Orlewska E. Podstawy Farmakoekonomiki (Principles in Pharmacoeconomics). UNIMED, Warsaw, 1999, textbook (Polish).
  2. Orlewska E., Nowakowska E. Farmakoekonomika dla studentów i absolwentów Akademii Medycznych (Pharmacoeconomics for students and graduets of Medical Universities); Medical University Publishing House, Poznan 2003, textbook (Polish).
  3. Orlewska E., Mierzejewski P. Polskie wytyczne przeprowadzania analiz farmakoekonomicznych - projekt (Polish guidelines for conducting pharmacoeconomic evaluations - project). Farmakoekonomika 2000, Suplement 1: 2-11.
  4. Orlewska E., Mierzejewski P. Polskie wytyczne przeprowadzania analizy finansowej – projekt (Polish guidelines for conducting financial analysis - project) Farmakoekonomika 2002, Suplement 1: 2-9.
  5. Orlewska E., Mierzejewski P. Polskie wytyczne obliczania kosztów w ocenie ekonomicznej programów zdrowotnych – projekt (Polish guidelines for cost calculation in the economic evaluation of healthcare programs – project). Farmakoekonomika 2003, 1: 3-6.
  6. Orlewska E. Economic aspects in medical decision making. Transplantation Proceedings. 2003, Vol.35, Issue 3, May 2003: 1227-1229.
  7. Orlewska E, Mierzejewski P. Project of Polish guidelines for conducting pharmacoeconomic evaluation in comparison to international health economic guidelines. Eur J of Health Economics 2003, 4:
  8. Orlewska E, Mierzejewski P. Polish Guidelines for Conducting Financial Analysis-Proposal. Value in Health 2004 1:.
  9. Walczak J, Annemans L, Orlewska E, et al. Wiarygodność metody porównania pośredniego w ocenie skuteczności alternatywnych interwencji (na przykładzie reboksetyny i wenlafaksyny w leczeniu depresji) Farmakoekonomika 2004, 3: 3-10.

 

    

IV  Systematic review:

 

1.      Orlewska E, Rowiński W. Ocena ekonomiczna leczenia schyłkowej niewydolności nerek – przegląd literatury (Economic evaluation of end-stage renal disease treatment – review). Farmakoekonomika 2002, 3: 3-10.

2.      Orlewska E.  Cost effectiveness of pegylated IFN-alfa2b and –alfa2a and ribavirin for chronic hepatitis C treatment. Expert Review of Pharmacoeconomics Outcomes Res 2004 4(5): 295-504.

 

Participation in courses in pharmacoeconomics:

               

York Expert Workshop in Socio-Economic Evaluation of Medicines, University of York, Centre for Health Economics (1999 r.)

Decision Analysis – Introduction, ISPOR 4th Annual International Meeting, Washington (1999)

Decision Analysis – Software Applications, ISPOR 2nd Annual European Conference, Edinburgh (1999)

Workshop on Advanced Pharmacoeconomics, Pharmacoeconomics Research Centre University of St Andrews (2000)

Cost-Effectiveness Analysis for Medical Technologies and Pharmaceuticals, Harvard School of Public Health, Boston, Massachusetts (2000)

General Health Index Instruments Seminar, 22nd Annual Meeting of the Society for Medical Decision Making (2000)

Meta-Analysis for Evidence-Based Medicine, 22nd Annual Meeting of the Society for Medical Decision Making (2000)

Statistical Considerations in Pharmacoeconomic Analyses, ISPOR 3nd Annual European Conference, Antwerp (2000)

Identification and Selection of Clinical Study Designs, ISPOR 6th Annual International Meeting, Washington (2001)

Measurement, Design and Analysis Methods for Health Outcomes Research, Harvard School of Public Health, Boston, Massachusetts (2001)

Prospective Economic Trials, ISPOR 7th Annual international Meeting, Washington (2002)

Evidence, Money and Drug Selection, WHO Essential drugs and Medicine policy Regional Office for Europe, The University of Birmingham and University of Newcastle,  Antalya 2002.

Evidence Based Medicine and its Application to Drug Utilisation, Vienna School of Clinical Research, Vienna 2002

Transferability of cost-effectiveness data between countries, ISPOR 5th Annual European Congress, Rotterdam (2002)

TreeAge Software Training Update, Barcelona (2003)